KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Acquisitions & Divestments: 2012-2024

Historic Change in Acquisitions & Divestments for Xenon Pharmaceuticals (XENE) over the last 12 years, with Dec 2024 value amounting to $700.3 million.

  • Xenon Pharmaceuticals' Change in Acquisitions & Divestments fell 31.28% to $113.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $616.2 million, marking a year-over-year decrease of 8.25%. This contributed to the annual value of $700.3 million for FY2024, which is 1.77% up from last year.
  • Xenon Pharmaceuticals' Change in Acquisitions & Divestments amounted to $700.3 million in FY2024, which was up 1.77% from $688.1 million recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Change in Acquisitions & Divestments peaked at $700.3 million during FY2024, and registered a low of $144.8 million during FY2021.
  • For the 3-year period, Xenon Pharmaceuticals' Change in Acquisitions & Divestments averaged around $549.7 million, with its median value being $688.1 million (2023).
  • Per our database at Business Quant, Xenon Pharmaceuticals' Change in Acquisitions & Divestments skyrocketed by 184.29% in 2020 and then plummeted by 32.58% in 2021.
  • Over the past 5 years, Xenon Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $214.7 million in 2020, then plummeted by 32.58% to $144.8 million in 2021, then soared by 80.05% to $260.6 million in 2022, then skyrocketed by 164.03% to $688.1 million in 2023, then climbed by 1.77% to $700.3 million in 2024.